For example, mutations of the epidermal growth factor receptor gene (EGFR) are found in approximately 30% of NSCLCs, especially in lung adenocarcinomas, and EGFR-tyrosine kinase inhibitors (TKIs) are particularly effective in these tumors [3], [4]. This evidence concerns the gene EGFR and lung adenocarcinoma.